Bluebook

Pharma Services: Drug Development April 2024

2024 - April: Report on M&A and financing activity in the pharma services drug development industry for CEOs and private equity professionals

Crosstree BlueBooks provide an executive review of key health sciences transactions, financial movements, and public market activity. BlueBooks also offer a glimpse of how valuations are changing and how recent trends may affect future transactions.

Highlights from this edition:

  • Creapharm was acquired by Myonex (Read more)
  • WindRose Health Investors announced its acquisition of Subject Well
  • Xaira Therapeutics, Inc. closed a $1,000MM Series A Financing, led by Arch Venture Partners, L.P., Sequoia Capital Operations LLC, New Enterprise Associates, Inc., Lightspeed Ventures, LLC, Lux Capital Management, LLC, SV Angel, Foresite Capital Management, LLC, Two Sigma Ventures, LP, F Prime, Inc., Byers Capital Management LLC

Download the BlueBook